TDMS Study 05132-06 Pathology Tables
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
Facility: Battelle Northwest
Chemical CAS #: 116-14-3
Lock Date: 10/14/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 58 58 58 58
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 4 16 15 17
Moribund Sacrifice 8 28 26 27
Accidently Killed 1
Survivors
Terminal Sacrifice 36 4 6 4
Animals Examined Microscopically 58 58 58 58
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (57) (55) (52) (50)
Sarcoma 1 (2%)
Intestine Large, Cecum (57) (52) (50) (46)
Leiomyosarcoma 1 (2%)
Sarcoma 1 (2%)
Intestine Small, Duodenum (55) (49) (49) (45)
Sarcoma 1 (2%)
Intestine Small, Jejunum (56) (47) (49) (45)
Intestine Small, Ileum (56) (49) (49) (45)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Sarcoma 1 (2%)
Liver (58) (58) (57) (57)
Hemangioma 4 (7%) 1 (2%) 1 (2%)
Hemangioma, Multiple 1 (2%) 1 (2%)
Hemangiosarcoma 20 (34%) 15 (26%) 19 (33%)
Hemangiosarcoma, Multiple 8 (14%) 12 (21%) 15 (26%)
Hepatocellular Carcinoma 4 (7%) 26 (45%) 16 (28%) 16 (28%)
Hepatocellular Carcinoma, Multiple 5 (9%) 7 (12%) 7 (12%)
Hepatocellular Adenoma 14 (24%) 12 (21%) 14 (25%) 9 (16%)
Hepatocellular Adenoma, Multiple 1 (2%) 7 (12%) 9 (16%) 8 (14%)
Histiocytic Sarcoma 1 (2%) 21 (36%) 19 (33%) 18 (32%)
Sarcoma 1 (2%)
Mesentery (10) (14) (7) (7)
Hemangiosarcoma 2 (14%)
Histiocytic Sarcoma 1 (10%) 1 (7%)
Leiomyosarcoma, Metastatic, Uterus 1 (7%)
Sarcoma 1 (7%) 1 (14%)
Pancreas (58) (57) (54) (57)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Page 2
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Sarcoma 1 (2%)
Stomach, Forestomach (58) (58) (57) (57)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (58) (58) (55) (55)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (58) (58) (57) (58)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (58) (57) (57) (57)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 3 (5%) 1 (2%)
Capsule, Adenoma 1 (2%)
Capsule, Carcinoma 1 (2%)
Adrenal Medulla (58) (57) (57) (56)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (58) (55) (54) (57)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (56) (55) (54) (56)
Histiocytic Sarcoma 1 (2%)
Pars Distalis, Adenoma 4 (7%) 5 (9%) 2 (4%) 6 (11%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (58) (58) (56) (56)
Follicular Cell, Adenoma 3 (5%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (57) (57) (55) (56)
Cystadenoma 2 (4%) 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 5 (9%) 4 (7%) 3 (5%)
Page 3
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Luteoma 2 (4%)
Sarcoma 1 (2%)
Periovarian Tissue, Histiocytic Sarcoma 1 (2%)
Uterus (58) (58) (55) (57)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%)
Cervix, Granular Cell Tumor NOS 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (58) (58) (56) (57)
Histiocytic Sarcoma 6 (10%) 5 (9%) 4 (7%)
Lymph Node (5) (6) (5) (6)
Axillary, Histiocytic Sarcoma 1 (20%)
Iliac, Histiocytic Sarcoma 1 (20%) 1 (17%) 1 (20%) 1 (17%)
Pancreatic, Histiocytic Sarcoma 1 (20%) 1 (17%)
Renal, Histiocytic Sarcoma 1 (17%) 2 (40%) 2 (33%)
Lymph Node, Bronchial (47) (44) (49) (46)
Histiocytic Sarcoma 4 (9%) 6 (12%) 4 (9%)
Sarcoma 1 (2%)
Lymph Node, Mandibular (46) (39) (43) (38)
Histiocytic Sarcoma 1 (2%) 3 (8%) 2 (5%) 2 (5%)
Lymph Node, Mesenteric (53) (50) (51) (53)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 6 (12%) 7 (14%) 6 (11%)
Lymph Node, Mediastinal (35) (42) (43) (36)
Histiocytic Sarcoma 1 (3%) 9 (21%) 9 (21%) 4 (11%)
Spleen (58) (58) (56) (57)
Histiocytic Sarcoma 1 (2%) 7 (12%) 8 (14%) 9 (16%)
Sarcoma 1 (2%)
Thymus (56) (52) (49) (48)
Histiocytic Sarcoma 2 (4%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (58) (56) (54) (56)
Carcinoma 1 (2%)
Skin (57) (58) (57) (58)
Hemangioma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (3%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (58) (58) (57) (58)
Osteosarcoma 1 (2%)
Rib, Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Skeletal Muscle (1)
Leiomyosarcoma, Metastatic, Uterus 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (58) (58) (56) (58)
Astrocytoma NOS 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (58) (58) (57) (57)
Alveolar/Bronchiolar Adenoma 5 (9%) 6 (11%) 3 (5%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Hemangiosarcoma, Metastatic, Liver 3 (5%)
Hemangiosarcoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 8 (14%) 6 (11%) 5 (9%)
Histiocytic Sarcoma 1 (2%) 16 (28%) 13 (23%) 13 (23%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (6) (4) (8)
Adenoma 3 (75%) 3 (50%) 7 (88%)
Bilateral, Adenoma 1 (13%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (58) (58) (57) (57)
Histiocytic Sarcoma 1 (2%) 7 (12%) 4 (7%) 3 (5%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Urinary Bladder (55) (53) (53) (46)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Page 5
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(58) *(58) *(58) *(58)
Histiocytic Sarcoma 1 (2%) 21 (36%) 19 (33%) 18 (31%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 5 (9%) 2 (3%) 3 (5%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 53 50 52
Total Primary Neoplasms 56 139 109 123
Total Animals with Benign Neoplasms 29 27 30 33
Total Benign Neoplasms 40 37 38 40
Total Animals with Malignant Neoplasms 14 49 46 50
Total Malignant Neoplasms 14 102 71 83
Total Animals with Metastatic Neoplasms 3 9 6 10
Total Metastatic Neoplasm 4 16 6 10
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2
Total Uncertain Neoplasms 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 58 58 58 58
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 4 13 20 20
Moribund Sacrifice 6 24 26 27
Survivors
Terminal Sacrifice 38 11 2 1
Animals Examined Microscopically 58 58 58 58
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (58) (58) (58) (58)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Lung 1 (2%)
Hemangioma 3 (5%) 3 (5%) 1 (2%)
Hemangioma, Multiple 7 (12%) 2 (3%) 1 (2%)
Hemangiosarcoma 5 (9%) 10 (17%) 22 (38%)
Hemangiosarcoma, Multiple 16 (28%) 17 (29%) 18 (31%)
Hepatocellular Carcinoma 9 (16%) 15 (26%) 26 (45%) 22 (38%)
Hepatocellular Carcinoma, Multiple 4 (7%) 9 (16%) 9 (16%) 6 (10%)
Hepatocellular Adenoma 16 (28%) 13 (22%) 7 (12%) 14 (24%)
Hepatocellular Adenoma, Multiple 7 (12%) 6 (10%) 9 (16%) 7 (12%)
Histiocytic Sarcoma 12 (21%) 7 (12%) 8 (14%)
Mesentery (2) (3) (2) (7)
Carcinoma, Metastatic, Lung 1 (33%)
Hemangioma 1 (14%)
Hemangiosarcoma 1 (14%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (14%)
Histiocytic Sarcoma 1 (50%)
Pancreas (58) (58) (56) (55)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Stomach, Forestomach (58) (58) (56) (56)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (3%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (58) (58) (58) (58)
Carcinoma, Metastatic, Lung 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (58) (58) (57) (58)
Adenoma 1 (2%) 1 (2%)
Islets, Pancreatic (58) (58) (56) (55)
Adenoma 1 (2%)
Thyroid Gland (58) (58) (57) (57)
Follicular Cell, Adenoma 3 (5%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (2) (2)
Carcinoma, Metastatic, Lung 1 (50%)
Hemangioma 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (58) (58) (58) (58)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (58) (58) (57) (57)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Lymph Node (3) (1) (2)
Renal, Histiocytic Sarcoma 1 (100%) 1 (50%)
Lymph Node, Bronchial (42) (42) (43) (33)
Histiocytic Sarcoma 3 (7%) 1 (3%)
Lymph Node, Mandibular (44) (37) (38) (42)
Histiocytic Sarcoma 2 (5%) 1 (3%)
Lymph Node, Mesenteric (57) (52) (51) (50)
Histiocytic Sarcoma 4 (8%) 1 (2%) 2 (4%)
Lymph Node, Mediastinal (37) (39) (40) (36)
Carcinoma, Metastatic, Lung 1 (3%) 1 (3%)
Histiocytic Sarcoma 2 (5%) 1 (3%)
Spleen (58) (58) (56) (56)
Hemangiosarcoma 2 (3%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 2 (4%)
Thymus (51) (49) (44) (46)
Histiocytic Sarcoma 1 (2%)
Thymoma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (58) (57) (58) (58)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (58) (58) (58) (58)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Skeletal Muscle (1)
Carcinoma, Metastatic, Lung 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (58) (58) (58) (58)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (58) (58) (58) (58)
Alveolar/Bronchiolar Adenoma 10 (17%) 7 (12%) 12 (21%) 4 (7%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 4 (7%) 3 (5%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Liver 2 (3%) 2 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 7 (12%) 15 (26%) 8 (14%)
Histiocytic Sarcoma 7 (12%) 4 (7%) 4 (7%)
Nose (58) (57) (56) (57)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (7) (10) (5) (7)
Adenoma 6 (86%) 9 (90%) 4 (80%) 5 (71%)
Carcinoma 1 (14%) 1 (10%) 1 (14%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (58) (58) (58) (58)
Carcinoma, Metastatic, Lung 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 3 (5%) 3 (5%) 2 (3%)
Urinary Bladder (58) (53) (53) (52)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(58) *(58) *(58) *(58)
Histiocytic Sarcoma 12 (21%) 7 (12%) 8 (14%)
Lymphoma Malignant Mixed 2 (3%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05132-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAFLUOROETHYLENE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 01:15:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 51 54 52
Total Primary Neoplasms 63 119 114 121
Total Animals with Benign Neoplasms 32 34 31 30
Total Benign Neoplasms 43 52 41 38
Total Animals with Malignant Neoplasms 18 43 49 50
Total Malignant Neoplasms 20 66 73 83
Total Animals with Metastatic Neoplasms 3 8 15 11
Total Metastatic Neoplasm 4 12 18 20
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------